Login
$ARWR
$44.25 +$0.04 (0.09%) After hours

$ARWR 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

Conference Call and Webcast Today, November 12, 2026, at 4:30 p.m. ET

04 Nov 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

–Existing $400 million facility prepaid at a $68 million discount to the contractual minimum repayment amount

04 Aug 2026 8-K: Results of Operations and Financial Condition

Conference Call and Webcast Today, August 4, 2026 at 4:30 p.m. ET

16 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

On June 12, 2026, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Dr. Matt Cohen, M.D., M.B.A., as a director of the Company, effective June 12, 2026.

07 May 2026 8-K: Results of Operations and Financial Condition

Conference Call and Webcast Today, May 7, 2026 at 4:30 p.m. ET

20 Mar 2026 8-K: Submission of Matters to a Vote of Security Holders

The following proposals were submitted to the stockholders of Arrowhead Pharmaceuticals, Inc. (the “Company”) at the 2026 Annual Meeting of Stockholders held on March 19, 2026:

05 Feb 2026 8-K: Results of Operations and Financial Condition

Conference Call and Webcast Today, February 5, 2026 at 4:30 p.m. ET

12 Jan 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

FIRST SUPPLEMENTAL INDENTURE, dated as of January 12, 2026, between Arrowhead Pharmaceuticals, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), to the...

09 Jan 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Introductory. Arrowhead Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) $625,000,000 principal amount of its 0% Convertible Se...

06 Jan 2026 8-K: Regulation FD Disclosure; Other Events

Obesity KOL Webinar ARO-INHBE and ARO-ALK7 Interim Phase 1/2a Clinical Data January 06, 2026

25 Nov 2025 8-K: Results of Operations and Financial Condition

Conference Call and Webcast Today, November 25, 2025 at 4:30 p.m. ET

18 Nov 2025 8-K: Other Events

REDEMPLO® (plozasiran) FDA Approval Conference Call November 18, 2025

12 Sep 2025 8-K: Other Events

COMPLAINT 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 UMHOFER, MITCHELL & KING LLP Matthew Donald Umhofer (SBN 206607) Margaret E. Dayton (SBN 274353) 767 S. Alameda St., Suite 270 Los Angeles, CA 90021 Tel...

11 Sep 2025 8-K: Other Events

1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ARROWHEAD PHARMACEUTICALS, INC., Plaintiff, v. IONIS PHARMACEUTICALS, INC., Defendant. C.A. No.________ JURY TRIAL DEMANDED PLAINTIFF’S COMPLAINT FOR DECLARATORY JUDGMENT...

02 Sep 2025 8-K: Entry into a Material Definitive Agreement

–Upon closing, Arrowhead will receive an upfront payment of $200 million

07 Aug 2025 8-K: Results of Operations and Financial Condition

Conference Call and Webcast Today, August 7, 2025 at 4:30 p.m. ET

12 May 2025 8-K: Results of Operations and Financial Condition

Conference Call and Webcast Today, May 12, 2025 at 4:30 p.m. ET

15 Apr 2025 8-K: Departure/Election of Directors or Officers; Compensation

PASADENA, Calif., Apr. 15, 2025 — Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that, effective May 13, 2025, Arrowhead’s Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and ...

19 Mar 2025 8-K: Submission of Matters to a Vote of Security Holders

The following proposals were submitted to the stockholders of Arrowhead Pharmaceuticals, Inc. (the “Company”) at the 2025 Annual Meeting of Stockholders held on March 12, 2025:

10 Feb 2025 8-K: Results of Operations and Financial Condition

Conference Call and Webcast Today, February 10, 2025 at 4:30 p.m. ET

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support